The Effect of the APOE ε2ε4 Genotype on the Development of Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI) in Non-Latino Whites

被引:14
作者
Ren, Dianxu [1 ,2 ]
Lopez, Oscar L. [3 ,4 ]
Lingler, Jennifer H. [1 ,4 ]
Conley, Yvette [1 ,5 ]
机构
[1] Univ Pittsburgh, Sch Nursing, 3500 Victoria St,360 Victoria Bldg, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA
[3] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Alzheimers Dis Res Ctr, Pittsburgh, PA 15261 USA
[5] Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; APOE epsilon 2 epsilon 4 genotype; mild cognitive impairment; APOLIPOPROTEIN-E; EPSILON-4; ALLELE; RISK-FACTOR; APOE; ASSOCIATION;
D O I
10.1111/jgs.16337
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
OBJECTIVES To examine the associations of APOE epsilon 2 epsilon 4 with the development of Alzheimer's disease (AD) and mild cognitive impairment (MCI) in non-Latino whites. DESIGN Prospective longitudinal cohort study. SETTING Uniform Data Set from the National Alzheimer's Coordinating Center (NACC) between 2005 and August 2018 (data freeze in September 2018). PARTICIPANTS Participants who were non-Latino white, had an APOE genotype available, first visit with dementia free for AD cohort and both dementia and MCI free for MCI cohort, and had a minimum of one follow-up visit (n = 11 871 for AD cohort, and n = 8305 for MCI cohort). MEASUREMENTS The incidences of AD and MCI were determined based on consensus meetings at each Alzheimer's disease center. We used NACC-derived variables to define individuals experiencing incidents of AD and MCI at the initial visit as well as the follow-up visits. RESULTS Among participants in the AD cohort (N = 11 871), epsilon 2 epsilon 4 accounted for 2.5%, epsilon 2 epsilon 2 accounted for 0.4%, epsilon 2 epsilon 3 accounted for 11.0%, epsilon 4 epsilon 4 accounted for 4.4%, epsilon 3 epsilon 4 accounted for 27.3%, and epsilon 3 epsilon 3 accounted for 54.4%. Over an average of 4.6 years follow-up, 1857 (15.6%) developed AD dementia, with the range from 6.0% to 35.2% across the six groups. Compared to epsilon 3 epsilon 3 carriers, epsilon 2 epsilon 4 carriers exhibited an increased risk of incident AD (18.4% vs 11.7%; adjusted hazard ratio [aHR] = 1.74; 95% confidence interval [CI] = 1.32-2.30; P < .0001). Among participants in the MCI cohort (N = 8305), the average follow-up was 4.7 years, and 1912 (23.0%) developed MCI, with the range from 20.4% to 33.9% across the six groups. Compared to epsilon 3 epsilon 3 carriers, epsilon 2 epsilon 4 carriers exhibited an increased risk of incident MCI (27.5% vs 21.5%; aHR = 1.52; 95% CI = 1.15-1.99; P = .003). CONCLUSIONS The APOE epsilon 2 epsilon 4 genotype is associated with the increased risk of AD and MCI in non-Latino whites.
引用
收藏
页码:1044 / 1049
页数:6
相关论文
共 14 条
[1]   APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old [J].
Berlau, Daniel J. ;
Corrada, Maria M. ;
Head, Elizabeth ;
Kawas, Claudia H. .
NEUROLOGY, 2009, 72 (09) :829-834
[2]   APOLIPOPROTEIN-E, EPSILON-4 ALLELE AS A MAJOR RISK FACTOR FOR SPORADIC EARLY AND LATE-ONSET FORMS OF ALZHEIMERS-DISEASE - ANALYSIS OF THE 19Q13.2 CHROMOSOMAL REGION [J].
CHARTIERHARLIN, MC ;
PARFITT, M ;
LEGRAIN, S ;
PEREZTUR, J ;
BROUSSEAU, T ;
EVANS, A ;
BERR, C ;
VIDAL, O ;
ROQUES, P ;
GOURLET, V ;
FRUCHART, JC ;
DELACOURTE, A ;
ROSSOR, M ;
AMOUYEL, P .
HUMAN MOLECULAR GENETICS, 1994, 3 (04) :569-574
[3]  
Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041
[4]   APOE and Alzheimer disease: a major gene with semi-dominant inheritance [J].
Genin, E. ;
Hannequin, D. ;
Wallon, D. ;
Sleegers, K. ;
Hiltunen, M. ;
Combarros, O. ;
Bullido, M. J. ;
Engelborghs, S. ;
De Deyn, P. ;
Berr, C. ;
Pasquier, F. ;
Dubois, B. ;
Tognoni, G. ;
Fievet, N. ;
Brouwers, N. ;
Bettens, K. ;
Arosio, B. ;
Coto, E. ;
Del Zompo, M. ;
Mateo, I. ;
Epelbaum, J. ;
Frank-Garcia, A. ;
Helisalmi, S. ;
Porcellini, E. ;
Pilotto, A. ;
Forti, P. ;
Ferri, R. ;
Scarpini, E. ;
Siciliano, G. ;
Solfrizzi, V. ;
Sorbi, S. ;
Spalletta, G. ;
Valdivieso, F. ;
Vepsalainen, S. ;
Alvarez, V. ;
Bosco, P. ;
Mancuso, M. ;
Panza, F. ;
Nacmias, B. ;
Bossu, P. ;
Hanon, O. ;
Piccardi, P. ;
Annoni, G. ;
Seripa, D. ;
Galimberti, D. ;
Licastro, F. ;
Soininen, H. ;
Dartigues, J-F ;
Kamboh, M. I. ;
Van Broeckhoven, C. .
MOLECULAR PSYCHIATRY, 2011, 16 (09) :903-907
[5]  
Houlden H, 1998, AM J MED GENET, V81, P117, DOI 10.1002/(SICI)1096-8628(19980207)81:1<117::AID-AJMG19>3.0.CO
[6]  
2-M
[7]   Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy [J].
Liu, Chia-Chan ;
Kanekiyo, Takahisa ;
Xu, Huaxi ;
Bu, Guojun .
NATURE REVIEWS NEUROLOGY, 2013, 9 (02) :106-118
[8]   The allele interaction between apolipoprotein ε2 and ε4 in Taiwanese Alzheimer's disease patients [J].
Lung, FW ;
Yen, YC ;
Chou, LJ ;
Hong, CJ ;
Wu, CK .
ACTA PSYCHIATRICA SCANDINAVICA, 2005, 111 (01) :38-43
[9]  
Oveisgharan S, 2018, NEUROLOGY, V90, pE2127, DOI [10.1212/WNL.0000000000005677, 10.1212/wnl.0000000000005677]
[10]   ASSOCIATION OF APOLIPOPROTEIN-E ALLELE EPSILON-4 WITH LATE-ONSET FAMILIAL AND SPORADIC ALZHEIMERS-DISEASE [J].
SAUNDERS, AM ;
STRITTMATTER, WJ ;
SCHMECHEL, D ;
GEORGEHYSLOP, PHS ;
PERICAKVANCE, MA ;
JOO, SH ;
ROSI, BL ;
GUSELLA, JF ;
CRAPPERMACLACHLAN, DR ;
ALBERTS, MJ ;
HULETTE, C ;
CRAIN, B ;
GOLDGABER, D ;
ROSES, AD .
NEUROLOGY, 1993, 43 (08) :1467-1472